TAKE - Take Solutions

📊 NSE: TAKE 🏢 Miscellaneous 📅 Last Updated: 12/14/2025 14:06

💰 Financial Performance

Revenue Growth by Segment

Life Sciences (LS) segment witnessed a de-growth of 64.35% in FY21. Supply Chain Management (SCM) segment witnessed a de-growth of 75.43% in FY21.

Geographic Revenue Split

High dependence on the US market (specific percentage not provided).

Profitability Margins

EBITDA margin was almost 19% in the last quarter (Q1 FY22). The company expects to stabilize at 19-20% EBITDA margins once a certain revenue run rate is hit.

EBITDA Margin

EBITDA margin was approximately 19% in the most recent quarter, with a target to stabilize at 19-20%.

Capital Expenditure

Not explicitly disclosed in the provided text, though 'Purchase of Property Plant and Equipment' is mentioned in the cash flow statement without a specific total value for the period.

Credit Rating & Borrowing

The company has about Rs. 500 crores in debt. Specific interest rate percentage is not mentioned, but liquidity is described as 'strained'.

⚙️ Operational Drivers

Raw Materials

Pass-through expenses (costs from sponsors given to sites in clinical trials).

Capacity Expansion

Not explicitly stated in units, but the company aims to scale up the business with the help of HIG.

Raw Material Costs

Cost of revenue includes pass-through expenses; specific percentage of revenue not provided.

Manufacturing Efficiency

Not applicable (service-based), but 'burning' of orders was constrained by COVID-19.

📈 Strategic Growth

Expected Growth Rate

19-20%

Growth Strategy

Strategic partnership with HIG to grow the Navitas brand; deleveraging to become a zero-debt company; diversification into related areas; and improving cash profitability.

Products & Services

Clinical trials, Life Sciences services, Supply Chain Management (exited in FY21).

Brand Portfolio

Navitas, APA Engineering (exited).

New Products/Services

Related areas of diversification not in conflict with the Navitas brand.

Market Expansion

Focus on the United States market to create value for the Navitas business.

Market Share & Ranking

Relatively small size of operations in a highly competitive industry.

Strategic Alliances

Strategic partnership with HIG (H.I.G. Capital).

🌍 External Factors

Industry Trends

Changing dynamics of the global pharma industry; shift towards Life Sciences (96% of revenue in FY21).

Competitive Landscape

Highly competitive industry with a relatively small size of operations.

Competitive Moat

Strategic partnership with HIG, which has a track record of creating shareholder value; the Navitas brand.

Macro Economic Sensitivity

Socio-economic conditions arising from the COVID-19 pandemic.

Consumer Behavior

Impacted by the COVID-19 pandemic and changing dynamics in the pharma industry.

Geopolitical Risks

Not explicitly mentioned, but fortunes are linked to the global pharma industry.

⚖️ Regulatory & Governance

Industry Regulations

Compliance with Indian Accounting Standards (Ind AS), specifically Ind AS 37 regarding provisions and contingent liabilities.

Taxation Policy Impact

Qualified opinion regarding internal financial controls over assessment of impairment in carrying value of tax assets and direct tax litigations.

Legal Contingencies

Pending direct tax litigations before various forums for various assessment years; impact of pending litigations as of March 31, 2025, disclosed in Note No. 4.